Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made
tremendous progress with five CAR T therapies approved by the US Food and Drug …

Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for
patients with certain haematological cancers, with multiple CAR T cell products currently …

Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …

As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T
cell therapies for hematologic malignancies. With the current transition of CAR T cell …

T cells engineered with chimeric antigen receptors (CARs) have revolutionized the field of
cell therapy and changed the paradigm of treatment for many patients with relapsed or …

Regular physical activity is associated with lower cancer incidence and mortality, as well as
with a lower rate of tumour recurrence. The epidemiological evidence is supported by …

The production of autologous T cells expressing a chimaeric antigen receptor (CAR) is time-
consuming, costly and occasionally unsuccessful. T-cell-derived induced pluripotent stem …

Adoptive cell therapy (ACT) has seen a steep rise of new therapeutic approaches in its
immune-oncology pipeline over the last years. This is in great part due to the recent …

Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which
autologous or allogeneic T cells are engineered to express a CAR targeting a membrane …

The remarkable success of cancer immunotherapies has provided new hope to cancer
patients. Unfortunately, a significant proportion of patients remain unable to respond to …